Please ensure Javascript is enabled for purposes of website accessibility



We have the knowledge and expertise to handle the most demanding and complex transactions and provide expert, efficient and cost effective services to all our clients. Our commercial understanding and experience of working with leading financial institutions, professional advisers and regulatory bodies enable us to add real value to our clients’ businesses.

View all services


Our experts provide independent guidance spanning advice and training to implementation and evaluation across sustainable investing, regulatory compliance and tech. Our tailored advice meets clients' specific needs, delivering flexible solutions and support.

View all Consulting


Our sector approach relies on smart collaboration between our business divisions, our service lines and our jurisdictions. These sector-based teams have a deep understanding of related businesses and industry dynamics. The specific combination of our highly informed experts helps our clients see around corners.

View all sectors


Ogier provides practical advice on BVI, Cayman Islands, Guernsey, Irish, Jersey and Luxembourg law through our global network of offices across the Asian, Caribbean and European timezones. Ogier is the only firm to advise on this unique combination of laws.

News and insights

Keep up to date with industry insights, analysis and reviews. Find out about the work of our expert teams and subscribe to receive our newsletters straight to your inbox.

Fresh thinking, sharper opinion.

About us

We get straight to the point, managing complexity to get to the essentials. Our global network of offices covers every time zone. 

No Content Set

Ogier Guernsey advises Stanley Capital on new investment structure and acquisition of Noden Pharma


01 October 2020


Ogier's Guernsey team has assisted Stanley Capital with the establishment of a Guernsey investment structure and the acquisition of Noden Pharma DAC and Noden Pharma USA (Noden), a leading speciality pharmaceutical company.

The multi-disciplinary Ogier team worked with Stanley Capital, lead counsel Willkie Farr & Gallagher (London) LLP and alterDomus. The team was led by partner Bryon Rees and senior associate Michelle Watson Bunn, with support from partners Tim Clipstone and Bryan De Verneuil-Smith, senior associate Charlotte Brown and associate Henry Simpson.

Bryon Rees commented: "We are delighted to have supported Stanley Capital and its advisors on this new investment structure and the initial acquisition, creating a solid base for future growth into a leading pharma platform."

Noden is focused on providing unique, complex to manufacture prescription medicines for cardiovascular patients who are intolerant to mainstream treatments. It is the first acquisition and a core platform for implementing a strategy to consolidate the mature product speciality pharma marketplace. Stanley Capital, working alongside Noden's management team, will pursue a value investment philosophy, targeting the acquisition of multiple drug portfolios to create a differentiated and highly cash generative portfolio of attractive medicines with established operational, technical, or patent-led barriers to entry.

Simon Cottle, partner at Stanley Capital, said: “The acquisition of Noden is the culmination of years of thematic research into the specialty pharmaceuticals sector, which identified the company as a strong buy and build platform. We look forward to working with Noden’s excellent management team and our industry advisors to build the company into a leading pharma platform, providing essential treatments for patients with unique and difficult to treat conditions.”

Stanley Capital is a private equity partnership pursuing repeatable relative value and thematic investment strategies in technology, healthcare, and sustainability, targeting businesses with enterprise values of $250mn to $2.5bn.

No Content Set